BRAF and Miyoshi myopathy: The combination of BRAF and MEK inhibitors, such as dabrafenib (D) and trametinib (T), actually represents the standard of care in metastatic or locally advanced BRAF V600 mutated malignant melanomas (MM) [1,2].